Pregnancy Outcomes in the Ozanimod Clinical Development Program in Patients With Ulcerative Colitis, Crohn's Disease, and Relapsing Multiple Sclerosis

Marla C. Dubinsky*, Lorna Charles, Krzysztof W. Selmaj, Giancarlo Comi, Anthony Krakovich, Melissa Rosen, C. Janneke van der Woude, Uma Mahadevan

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

8 Downloads (Pure)

Abstract

This study evaluated pregnancy outcomes in patients with ulcerative colitis, Crohn's disease, or multiple sclerosis and in healthy volunteers treated with ozanimod. There was no increased incidence of fetal abnormalities or adverse pregnancy outcomes with ozanimod exposure during early pregnancy.
Original languageEnglish
Article numberizae011
Number of pages4
JournalInflammatory Bowel Diseases
DOIs
Publication statusE-pub ahead of print - 24 Jan 2024

Bibliographical note

© 2024 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.

Fingerprint

Dive into the research topics of 'Pregnancy Outcomes in the Ozanimod Clinical Development Program in Patients With Ulcerative Colitis, Crohn's Disease, and Relapsing Multiple Sclerosis'. Together they form a unique fingerprint.

Cite this